Edwards Lifesciences Corporation (EW) Shares Bought by Koch Industries Inc.

Koch Industries Inc. grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 28,363.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,397,254 shares of the medical research company’s stock after buying an additional 1,392,345 shares during the period. Edwards Lifesciences Corporation makes up 0.4% of Koch Industries Inc.’s investment portfolio, making the stock its 13th largest holding. Koch Industries Inc. owned about 0.66% of Edwards Lifesciences Corporation worth $1,386,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Edwards Lifesciences Corporation by 2.0% in the 2nd quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock worth $2,453,311,000 after purchasing an additional 406,901 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Edwards Lifesciences Corporation by 0.8% in the 2nd quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock worth $1,668,309,000 after purchasing an additional 105,819 shares in the last quarter. State Street Corp lifted its holdings in shares of Edwards Lifesciences Corporation by 1.7% in the 1st quarter. State Street Corp now owns 9,388,994 shares of the medical research company’s stock worth $883,219,000 after purchasing an additional 157,844 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Edwards Lifesciences Corporation by 161.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after purchasing an additional 3,277,726 shares in the last quarter. Finally, Winslow Capital Management LLC lifted its holdings in shares of Edwards Lifesciences Corporation by 0.8% in the 1st quarter. Winslow Capital Management LLC now owns 2,654,484 shares of the medical research company’s stock worth $249,707,000 after purchasing an additional 19,887 shares in the last quarter. Institutional investors own 82.12% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Edwards Lifesciences Corporation (EW) Shares Bought by Koch Industries Inc.” was first posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.thestockobserver.com/2017/10/13/edwards-lifesciences-corporation-ew-shares-bought-by-koch-industries-inc.html.

In related news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $114.80, for a total transaction of $3,776,920.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 25,000 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $116.00, for a total value of $2,900,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 182,201 shares of company stock valued at $20,768,154. 2.13% of the stock is owned by company insiders.

A number of brokerages recently issued reports on EW. Bank of America Corporation increased their target price on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, July 27th. BidaskClub cut Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Cowen and Company reiterated a “buy” rating and issued a $135.00 target price on shares of Edwards Lifesciences Corporation in a report on Thursday. SunTrust Banks, Inc. increased their target price on Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a report on Monday, July 17th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $155.00 target price (up from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Seven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $120.75.

Shares of Edwards Lifesciences Corporation (EW) traded down 1.32% during midday trading on Friday, hitting $108.75. The stock had a trading volume of 642,823 shares. The stock’s 50-day moving average is $111.51 and its 200-day moving average is $111.23. The stock has a market cap of $23.11 billion, a PE ratio of 41.67 and a beta of 0.62. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. The firm had revenue of $842.00 million for the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.76 earnings per share. Equities analysts anticipate that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply